Idorsia Ltd

IDIA

Equity

ISIN CH0363463438 / Valor 36346343

SIX Swiss Exchange (2024-11-20)

CHF 0.72-0.34%

Idorsia Ltd
UMushroom community rating:

4.60 10 votes No rating yet

NegativeNeutralPositive

About company

Idorsia Ltd is a pharmaceutical company focused on discovering, developing, and commercializing innovative medicines to improve patient outcomes. The company is dedicated to advancing medical research and bringing new treatments to market to address unmet medical needs. With a strong commitment to innovation and patient care, Idorsia aims to make a meaningful impact on the healthcare industry and improve the lives of patients worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Net Revenue

Idorsia Ltd reported net revenues of CHF 26 million in the first half of 2024, primarily driven by QUVIVIQ product sales and contract revenue recognized in connection with Owkin. This is a decrease from CHF 51 million in the first half of 2023, which included CHF 32 million sales of PIVLAZ in Japan.

Operating Expenses

US GAAP operating expenses for Idorsia Ltd in the first half of 2024 amounted to CHF 94 million, significantly lower than the CHF 426 million reported in the first half of 2023. This reduction was influenced by extraordinary income of CHF 125 million from the Viatris deal.

Net Loss

Idorsia Ltd's US GAAP net loss in the first half of 2024 was CHF 79 million, a substantial improvement from the CHF 405 million net loss in the first half of 2023. The decrease in net loss is mainly attributable to the one-off income related to the Viatris deal and lower operating expenses.

Non-GAAP Net Loss

On a non-GAAP basis, Idorsia Ltd reported a net loss of CHF 183 million in the first half of 2024. The difference of CHF 104 million compared to the US GAAP net income was mainly due to the one-off effect of the Viatris deal, depreciation and amortization, and share-based compensation.

Liquidity and Debt

As of June 30, 2024, Idorsia Ltd's liquidity stood at CHF 237 million. The company's total debt was CHF 1,294 million, which includes a convertible loan of CHF 335 million, a convertible bond of CHF 797 million, and other financial debt of CHF 162 million.

Summarized from source with an LLMView Source

Key figures

-62.9%1Y

-95.7%3Y

-97.1%5Y

Performance

109%1Y

77.8%3Y

64.9%5Y

Volatility